1. Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence.
- Author
-
Yoo TR, Lee JY, Park H, Cho WK, Jeon S, Jun HR, Lee SB, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH, Ahn SH, Jeong JH, Kim JE, Ahn JH, Jung KH, Kim SB, Lee HJ, Gong G, Kim J, and Chun SM
- Subjects
- Humans, Female, Middle Aged, Aged, Adult, Retrospective Studies, Biomarkers, Tumor blood, Biomarkers, Tumor genetics, Prospective Studies, Longitudinal Studies, Breast Neoplasms genetics, Breast Neoplasms blood, Breast Neoplasms pathology, Breast Neoplasms therapy, Circulating Tumor DNA blood, Circulating Tumor DNA genetics, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local blood, Mutation
- Abstract
The prevalence and dynamics of circulating tumor DNA (ctDNA) in patients with breast cancer recurrence or de novo metastatic cancer were examined in a retrospective analysis of a prospective observational cohort. Twenty-three recurrent/metastatic breast cancer cases (8 locoregional, 15 distant metastasis) were enrolled, and sequential plasma samples were obtained. Anchor mutations were selected from the target sequencing of each patient's primary and/or metastatic tumor. An in-house developed assay (UHS assay) was employed for a tumor-informed ctDNA assay during treatment and follow-up. A median of three (range 1-5) anchor mutations per case were applied for ctDNA detection. ctDNA was detected in 14 (63.6%, 14/22) cases at the time of enrollment and 18 (78.5%, 18/23) cases during follow-up. More anchor mutations and higher tumor burden were significantly related to higher ctDNA positive rates (p-value 0.036, 0.043, respectively). The mean enriched variant allele frequency (eVAF) at each time point was significantly higher for stable or progressive disease responses (ANOVA test p-value < 0.001). Eight patients showed an increase in their ctDNA eVAF prior to clinical progression with a mean lead time of 6.2 months (range 1.5-11 months). ctDNA dynamics measured using personalized assay reflected the clinical course of breast cancer recurrence., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF